Contact Us
Drug Search Results
More Filters [+]

Defactinib

Alternative Names: defactinib, vs-6063, pf-04554878
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FAK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Breakthrough Therapy - Ovarian Cancer
Orphan Drug - Ovarian Cancer
Orphan Drug - Pancreatic Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Verastem
Company Location: NEEDHAM MA 02494
Company CEO: Brian M. Stuglik
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Defactinib

Countries in Clinic: Belgium, France, Germany, Italy, Spain, United Kingdom, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Ovarian Cancer

Phase 2: Adenocarcinoma|Astrocytoma|Cervical Cancer|Endometrioid Carcinoma|Gastrointestinal Cancer|Glioblastoma|Glioma|Melanoma|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Uveal Melanoma

Phase 1: Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
VS-6766-301

P3

Unknown Status

Ovarian Cancer

2030-11-30

5G-RUBY

P2

Recruiting

Glioblastoma|Glioma|Astrocytoma

2029-09-30

AAAV0009

P2

Recruiting

Gastrointestinal Cancer

2028-11-30

DETERMINE

P2

Recruiting

Melanoma

2028-01-15

Recent News Events

Date

Type

Title

12/18/2024

News Article

 Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

11/06/2024

News Article

 Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

10/31/2024

News Article

 Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

10/09/2024

News Article

 Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

05/03/2024

PubMed

 Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.

02/12/2024

PubMed

 Roles and inhibitors of FAK in cancer: current advances and future directions.

02/09/2024

PubMed

 Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions